Search Results - "ALTISENT, C"

Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes by Altisent, C., Martorell, M., Crespo, A., Casas, L., Torrents, C., Parra, R.

“…Aim This observational study was undertaken with the aim to describe the characteristics and evaluate the outcomes of prophylactic treatment in children with…”
Get full text

Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis by Moreno-Castaño, A B, Ramos, A, Pino, M, Parra, R, Altisent, C, Vidal, F, Corrales, I, Borràs, N, Torramadé-Moix, S, Palomo, M, Escolar, G, Diaz-Ricart, M

“…Identification of qualitative variants of von Willebrand disease (VWD) can be a diagnostic challenge because of discrepant results obtained in the multiple…”
Get full text

Diagnostic delay in acquired haemophilia: Analysis of causes and consequences in a 20‐year Spanish cohort by Pardos‐Gea, J., Fernández‐Díaz, N., Parra, R., Cortina, V., Altisent, C.

Get full text

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report by ASTERMARK, J., ALTISENT, C., BATOROVA, A., DINIZ, M. J., GRINGERI, A., HOLME, P. A., KARAFOULIDOU, A., LOPEZ-FERNÁNDEZ, M. F., REIPERT, B. M., ROCINO, A., SCHIAVONI, M., Von DEPKA, M., WINDYGA, J., FIJNVANDRAAT, K.

“…The development of inhibitors to the infused factor in patients with haemophilia is a serious clinical problem. Recent evidence suggests that alongside the…”
Get full text

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A by García-Dasí, M., Aznar, J. A., Jiménez-Yuste, V., Altisent, C., Bonanad, S., Mingot, E., Lucía, F., Giménez, F., López, M. Fernanda, Marco, P., Pérez, R., Fernández, M. Á., Paloma, M. J., Galmes, B., Herrero, S., García-Talavera, J. A.

“…Summary Treatment adherence in adolescents with chronic diseases is around 50%, and failure is more common in preventive therapy. In haemophilia, contradictory…”
Get full text

Moderate and severe haemophilia in Spain: An epidemiological update by Aznar, J. A., Altisent, C., Álvarez‐Román, M. T., Bonanad, S., Mingot‐Castellano, M. E., López, M. F.

Get full text

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER) by Napolitano, Mariasanta, Giansily-Blaizot, Muriel, Dolce, Alberto, Schved, Jean F, Auerswald, Guenter, Ingerslev, Jørgen, Bjerre, Jens, Altisent, Carmen, Charoenkwan, Pimlak, Michaels, Lisa, Chuansumrit, Ampaiwan, Di Minno, Giovanni, Caliskan, Umran, Mariani, Guglielmo

“…Because of the very short half-life of factor VII, prophylaxis in factor VII deficiency is considered a difficult endeavor. The clinical efficacy and safety of…”
Get full text

Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations by HERMANS, C., ALTISENT, C., BATOROVA, A., CHAMBOST, H., DE MOERLOOSE, P., KARAFOULIDOU, A., KLAMROTH, R., RICHARDS, M., WHITE, B., DOLAN, G.

“…Although most surgical and invasive procedures can be performed safely in patients with haemophilia, the optimal level and duration of replacement therapy…”
Get full text

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study by Liesner, R. J., Abashidze, M., Aleinikova, O., Altisent, C., Belletrutti, M. J., Borel‐Derlon, A., Carcao, M., Chambost, H., Chan, A. K. C., Dubey, L., Ducore, J., Fouzia, N. A., Gattens, M., Gruel, Y., Guillet, B., Kavardakova, N., El Khorassani, M., Klukowska, A., Lambert, T., Lohade, S., Sigaud, M., Turea, V., Wu, J. K. M., Vdovin, V., Pavlova, A., Jansen, M., Belyanskaya, L., Walter, O., Knaub, S., Neufeld, E. J.

“…Introduction Nuwiq® (Human‐cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein…”
Get full text

Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study) by Rocino, A., Cortesi, P. A., Scalone, L., Mantovani, L. G., Crea, R., Gringeri, A.

“…Introduction Although immune tolerance induction (ITI) is considered the first choice treatment to eradicate inhibitors in haemophilia A patients, little is…”
Get full text

Sodium content in products used to treat haemophilia by Altisent, C., Martorell, M., de la Sierra, A.

Get full text

Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey by Windyga, J., Dolan, G., Altisent, C., Katsarou, O., López Fernández, M.-F., Zülfikar, B.

“…Introduction Desamino D‐arginine vasopressin (DDAVP or desmopressin) is a useful and effective haemostatic treatment for patients with von Willebrand Disease…”
Get full text

International cross-cultural validation study of the Canadian Haemophilia Outcomes: Kids' Life Assessment Tool by McCusker, P. J., Fischer, K., Holzhauer, S., Meunier, S., Altisent, C., Grainger, J. D., Blanchette, V. S., Burke, T. A., Wakefield, C., Young, N. L.

“…Summary Health‐related quality of life (HRQoL) assessment is recognized as an important outcome in the evaluation of different therapeutic regimens for persons…”
Get full text

Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey by Windyga, J., Dolan, G., Altisent, C., Katsarou, O., López Fernández, M.-F., Zülfikar, B.

“…Introduction The bleeding propensity in von Willebrand disease (VWD) is usually moderate or mild and patients with VWD do not need continuous treatment, but do…”
Get full text

Advanced cell‐based modeling of the royal disease: characterization of the mutated F9 mRNA by Martorell, L., Luce, E., Vazquez, J.L., Richaud‐Patin, Y., Jimenez‐Delgado, S., Corrales, I., Borras, N., Casacuberta‐Serra, S., Weber, A., Parra, R., Altisent, C., Follenzi, A., Dubart‐Kupperschmitt, A., Raya, A., Vidal, F., Barquinero, J.

“…Essentials The Royal disease (RD) is a form of hemophilia B predicted to be caused by a splicing mutation. We generated an iPSC‐based model of the disease…”
Get full text

Continuous infusion in haemophilia: current practice in Europe by BATOROVA, A., HOLME, P., GRINGERI, A., RICHARDS, M., HERMANS, C., ALTISENT, C., LOPEZ-FERNÁNDEZ, M., FIJNVANDRAAT, K.

“…Continuous infusion (CI) of factor VIII (FVIII) is an effective method for replacement therapy in haemophilia. Recently, concerns have been raised regarding…”
Get full text

Advanced cell‐based modeling of the royal disease: characterization of the mutated F9mRNA by Martorell, L., Luce, E., Vazquez, J.L., Richaud‐Patin, Y., Jimenez‐Delgado, S., Corrales, I., Borras, N., Casacuberta‐Serra, S., Weber, A., Parra, R., Altisent, C., Follenzi, A., Dubart‐Kupperschmitt, A., Raya, A., Vidal, F., Barquinero, J.

“…Essentials The Royal disease (RD) is a form of hemophilia B predicted to be caused by a splicing mutation. We generated an iPSC-based model of the disease…”
Get full text

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia by RENTZ, A., FLOOD, E., ALTISENT, C., BULLINGER, M., KLAMROTH, R., GARRIDO, R. P., SCHARRER, I., SCHRAMM, W., GORINA, E.

“…Co‐morbidities of haemophilia, such as arthropathy and blood‐borne infections, can adversely affect the quality of life of adult patients with haemophilia. The…”
Get full text

The study of the effect of splicing mutations in von Willebrand factor using RNA isolated from patients’ platelets and leukocytes by CORRALES, I., RAMÍREZ, L., ALTISENT, C., PARRA, R., VIDAL, F.

“…Background: In von Willebrand factor (VWF) the effect of mutations potentially affecting mRNA processing or splicing is less predictable than that of other…”
Get full text

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres by MORFINI, M., AUERSWALD, G., KOBELT, R. A., RIVOLTA, G. F., RODRIGUEZ-MARTORELL, J., SCARAGGI, F. A., ALTISENT, C., BLATNY, J., BOREL-DERLON, A., ROSSI, V.

“…Many patients with haemophilia develop inhibitors to factor VIII and require bypassing agents to provide haemostatic cover for limb‐ or life‐threatening…”
Get full text